To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD

NCT01495221 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy)

Interventions

DRUG: Alfilbercept

Sponsor

Vitreous -Retina- Macula Consultants of New York